Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p412 | Osteoporosis: treatment | ECTS2016

The value of the central vertebral height restoration by kyphoplasty for treatment of biconcave vertebral compression fractures

Zhang Jia , Li Qiang , Zhu Sheng

Purpose: To study the value of the central vertebral height restoration by kyphoplasty for treatment of biconcave vertebral compression fractures.Method: Review the patients with the single biconcave vertebral compression fracture receiving kyphoplasty treatment from 2006 to 2013 (49 cases, 13 males and 36 females) According to Genant classification, with the central vertebral compression ratio, they are divided into type II (<25%, 11 cases), type II...

ba0007p136 | (1) | ICCBH2019

Intravenous bisphosphonate treatment in severe infantile hypercalcemia associated with Williams Syndrome

Guarneri Alissa M , Patel Nisha , Bowden Sasigarn A

Background: Infantile hypercalcemia occurs in ~15% of patients with Williams Syndrome (WS) and is typically mild. Severe hypercalcemia has been reported in infants/toddlers with WS, requiring treatment with intravenous (IV) saline hydration, furosemide, calcitonin, calcium and vitamin D restriction, and in some cases IV bisphosphonates.Presenting problem: Three cases of infants with WS age 9–13 months presented with severe hypercalcemia, failure to ...

ba0001oc2.2 | Bone quality and fracture repair - animal models | ECTS2013

Intermittent human parathyroid hormone (1–84) treatment improves bone mass and bone defect healing in rats with type 2 diabetes mellitus

Hamann Christine , Picke Ann-Kristin , Rauner Martina , Bernhardt Ricardo , Campbell Graeme , Gluer Claus-Christian , Hofbauer Lorenz C

The pathogenesis of skeletal fragility in diabetes mellitus is poorly defined and efficient therapies are limited. Zucker diabetic fatty (ZDF) rats with type 2 diabetes mellitus display low bone mass and delayed bone defect healing. We tested whether intermittent treatment with human parathyroid hormone 1–84 (PTH) increases bone mass and bone defect regeneration in diabetic rats.A subcritical gap defect was created at the femur of 10 weeks old diabe...

ba0001oc5.5 | Treatment of osteoporosis | ECTS2013

Bone anabolic efficacy and safety of ba058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis

Hattersley Gary , Bilezikian John , Guerriero Jonathan , Kumar Prasanna , Zanchetta Jose , Lyttle C Richard , O'Dea Louis Saint L

A randomized, placebo-controlled phase 2 study evaluated the safety and efficacy of BA058, an analog of hPTHrP(1–34), in postmenopausal women with severe osteoporosis. 221 patients were randomized to received BA058 20, 40, and 80 μg, placebo or teriparatide (TP) 20 μg, by daily s.c. injection. 184 (83%) patients completed an initial 24 weeks of treatment. The mean percent change in lumbar spine BMD at 24 weeks was 1.6% with placebo, 6.7% with BA058 80 μg, a...

ba0001pp40 | Bone biomechanics and quality | ECTS2013

Prediction of vertebral body stiffness in patients with multiple myeloma using qCT-based finite element models

Campbell Graeme , Graeff Christian , Giravent Sarah , Thomsen Felix , Pena Jaime , Wulff A , Gunther A , Gluer Claus C , Borggrefe Jan

Multiple myeloma (MM) is associated with lytic bone destruction leading to high fracture incidence in the vertebrae. Accurate assessment of fracture risk is required for physicians to determine the necessity for surgery. This risk is currently determined by examining lesion size or number; however, this method does not consider the biomechanical attributes of the bone. Finite element (FE) modelling can simulate mechanical loading on vertebral bodies, and estimate mechanical in...

ba0001pp215 | Cell biology: osteoclasts and bone resorption | ECTS2013

The F-actin modulator SWAP-70 is required for proper podosome dynamics in osteoclasts

Roscher Anne , Glosmann Martin , Reinhold G Erben , Lutter Anne-Helen , Chopin Michael , Lorenz C Hofbauer , Jessberger Rolf , Garbe Annette

Bone remodeling is a crucial process to maintain a healthy bone structure in order to avoid diseases like osteoporosis or osteopetrosis. Osteoclasts contribute to this process by resorbing old and brittle bone allowing osteoblasts to renew the bone substance. During resorption osteoclasts rearrange their actin cytoskeleton by forming an F-actin ring generating a resorptive cavity on the bone surface. Recently, we reported that the F-actin binding protein SWAP-70 regulates oste...

ba0001pp238 | Cell biology: osteocytes | ECTS2013

Calcium Sensing Receptor is expressed on/in osteocyte-like MLOY4 culture and modulated by strontium ranelate

Aveline Priscilla C , Toumi Hechmi , Lespessailles Eric , Boudot Cedric , Mentaverri Romuald , Rochefort Gael Y , Benhamou Claude-Laurent

Introduction: The calcium sensing receptor presence (CaSR) at the surface of the osteocytes has never been clearly investigated. The CaSR are known to be express on osteoblasts. Osteocytes being old osteoblasts embedded in the matrix, this expression of CaSR is likely, and could constitute a key role to calcium signalling.Strontium ranelate (SrRan) has shown to activate osteoblasts by fixation on CaSR (Chattopadhyay N 2007, Biochem Pharmacol; Hu...

ba0002p97 | (1) | ICCBH2013

Vitamin D status and bone health in survivors of childhood lymphoblastic leukemia

Schundeln Michael M , Hauffa Pia K , Goretzki Sara C , Lahner Harald , Marschke Laura , Eggert Angelika , Hauffa Berthold P , Grasemann Corinna

Introduction: Lymphoblastic leukemia is the predominant form of childhood malignancies with survival rates of >80%. Late effects of cancer and treatment can affect endocrine function and may account for acute and chronic impairment of bone health.Aim and design: To assess bone health in pediatric patients after therapy for lymphoblastic leukemia we initiated a clinical trial investigating clinical and biochemical parameters of growth, puberty, bone t...

ba0002p181 | (1) | ICCBH2013

Long-term imiglucerase/alglucerase treatment in Latin American children with type 1 Gaucher disease: lessons from the International Collaborative Gaucher Group (ICGG) Gaucher Registry

Camelo Jr Jose Simon , Cabello Juan Francisco , Drelichman Guillermo G , Kerstenetzky Marcelo M , Sarmiento Isabel C , Linares Adriana

Objective: Evaluate the clinical characteristics of all Latin American pediatric patients with Gaucher disease type 1 (GD1) enrolled in the ICGG Gaucher Registry at baseline and investigate long-term outcomes and clinical benefit of prolonged imiglucerase/alglucerase therapy in patients with manifestations of GD1 at baseline.Methods: All Latin American patients with GD1 in the ICGG Gaucher Registry (NCT00358943) who were <18 years of age at the start...

ba0003pp214 | Osteoporosis: evaluation and imaging | ECTS2014

Bone marrow densitometry by clinical high resolution computed tomography of human vertebrae

Pena Jaime , Campbell Graeme , Damm Timo , Barkmann Reinhard , Waldhausen Sonja , Thomsen Felix , Krause Matthias , Puschel Klaus , Gluer Claus C

Bone mineral density (BMD) as measured by quantitative computed tomography (QCT) is biased by the variable marrow composition since marrow fat reduces the apparent BMD. We developed a marrow densitometry (MD) method that identifies subvolumes in the vertebrae that consist of bone marrow only (bone voids) and determines their average mineral equivalent density values. The method was developed for use with in vivo high resolution QCT (HR-QCT). HR-QCT still has limited s...